Viome

Executive Summary

Viome is a leading private health-tech company that combines at-home microbiome testing with AI-driven personalized nutrition and supplement recommendations. Its proprietary metatranscriptomic RNA sequencing technology assesses microbial activity, enabling tailored interventions across digestive, metabolic, mental, and immune health. Founded in 2016 and headquartered in South San Francisco, Viome has raised over $250 million to scale its platform and commercialize direct-to-consumer health insights. The company targets a growing market focused on preventative wellness and precision nutrition, leveraging a subscription model for recurring revenue. Despite its innovative approach and substantial funding, Viome faces challenges typical of the direct-to-consumer health space, including scientific validation of its algorithms, regulatory scrutiny, and competition from other microbiome testing companies. Its commercial stage indicates existing revenue, but profitability or unit economics are not publicly disclosed. The company's long-term success hinges on clinical evidence supporting its recommendations, expansion into B2B channels or partnerships, and potential FDA clearances for specific diagnostic claims.

Upcoming Catalysts (preview)

• Q3 2026Publication of key clinical validation study for Gut Intelligence test70% success
• Q4 2026Partnership with major pharmacy or telehealth retailer for distribution50% success
• H1 2027Launch of new at-home test for metabolic health with FDA 510(k) clearance40% success